[HTML][HTML] Cavitating pulmonary tuberculosis: a global challenge
W Saeed - Clinical medicine, 2012 - ncbi.nlm.nih.gov
Tuberculosis (TB) remains a major challenge and burden on healthcare with devastating
fallout. The World Health Organization (WHO) has declared it a 'global emergency'. In the …
fallout. The World Health Organization (WHO) has declared it a 'global emergency'. In the …
Cavitating pulmonary tuberculosis: a global challenge
G Bothamley, M Lipman, OM Kon - Clinical Medicine, 2012 - rcpjournals.org
Editor–We were concerned that a new treatment for tuberculosis (TB) was being advocated
without the benefit of a randomised controlled trial (W Saeed, Clin Med February 2012 pp 40 …
without the benefit of a randomised controlled trial (W Saeed, Clin Med February 2012 pp 40 …
[HTML][HTML] Outcomes of extended duration therapy for drug-susceptible cavitary pulmonary tuberculosis
H Lee, JW Sohn, YS Sim, TR Shin… - Annals of Translational …, 2020 - ncbi.nlm.nih.gov
Background Extending the continuation phase treatment duration is recommended to
improve outcomes of drug-susceptible cavitary pulmonary tuberculosis (TB), but limited data …
improve outcomes of drug-susceptible cavitary pulmonary tuberculosis (TB), but limited data …
[HTML][HTML] Clinical factors associated with cavitary tuberculosis and its treatment outcomes
Cavitary pulmonary tuberculosis (TB) is associated with poor outcomes, treatment
recurrence, higher transmission rates, and the development of drug resistance. However …
recurrence, higher transmission rates, and the development of drug resistance. However …
[HTML][HTML] The value of initial cavitation to predict re-treatment with pulmonary tuberculosis
Q Huang, Y Yin, S Kuai, Y Yan, J Liu, YY Zhang… - European journal of …, 2016 - Springer
Objective Pulmonary cavitation is the classic hallmark of pulmonary tuberculosis (PTB) and
is the site of very high mycobacterial burden associated with antimycobacterial drug …
is the site of very high mycobacterial burden associated with antimycobacterial drug …
Cavitary tuberculosis: the gateway of disease transmission
ME Urbanowski, AA Ordonez… - The Lancet Infectious …, 2020 - thelancet.com
Tuberculosis continues to be a major threat to global health. Cavitation is a dangerous
consequence of pulmonary tuberculosis associated with poor outcomes, treatment relapse …
consequence of pulmonary tuberculosis associated with poor outcomes, treatment relapse …
Risk factors for pulmonary cavitation in tuberculosis patients from China
L Zhang, Y Pang, X Yu, Y Wang, J Lu… - Emerging microbes & …, 2016 - Taylor & Francis
Pulmonary cavitation is one of the most frequently observed clinical characteristics in
tuberculosis (TB). The objective of this study was to investigate the potential risk factors …
tuberculosis (TB). The objective of this study was to investigate the potential risk factors …
[HTML][HTML] A case report of persistent drug-sensitive pulmonary tuberculosis after treatment completion
SA Vashakidze, A Chandrakumaran, M Japaridze… - BMC Infectious …, 2022 - Springer
Abstract Background Mycobacterium tuberculosis (Mtb) has been found to persist within
cavities in patients who have completed their anti-tuberculosis therapy. The clinical …
cavities in patients who have completed their anti-tuberculosis therapy. The clinical …
Is the Beijing strain of Mycobacterium tuberculosis associated with cavitary lung disease?
HJ Chapman, SA Phillips, JL Hosford… - Infection, Genetics and …, 2015 - Elsevier
We conducted a cross-sectional study to describe clinical characteristics of patients with
pulmonary tuberculosis with and without evidence of pulmonary cavitation on chest …
pulmonary tuberculosis with and without evidence of pulmonary cavitation on chest …
[HTML][HTML] Proposed approach for 4-month treatment of culture-negative pulmonary tuberculosis in adults
Y Hamada, L Paulos, NG Baruch… - Annals of the American …, 2016 - atsjournals.org
Standard treatment for pan-sensitive pulmonary tuberculosis (TB) includes a 2-month initial
phase of isoniazid (H), rifampicin (R), pyrazinamide (Z), and ethambutol (E) followed by a 4 …
phase of isoniazid (H), rifampicin (R), pyrazinamide (Z), and ethambutol (E) followed by a 4 …